Novavax (NVAX) Announces 'Going Concern' Qualification
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
February 28, 2023 4:02 PM ESTAchieved revenues in fourth quarter 2022 of $357 million and full year 2022 of $2.0 billionAppointed John C. Jacobs as President and Chief Executive OfficerUpdated U.S. government agreement to include up to 1.5 million additional doses of Novavax's COVID-19 vaccine for delivery in 2023Expanded Nuvaxovid label in adult booster and adolescent primary seriesInitiated Phase 2 trial of COVID-19-Influenza Combination and stand-alone influenza vaccine candidatesCompany to host conference call today at 4:30 p.m. ET
GAITHERSBURG, Md., Feb. 28, 2023... More
